Literature DB >> 33723301

A systematic review and meta-analysis of treatment-related toxicities of curative and palliative radiation therapy in non-small cell lung cancer.

M Or1, B Liu2, J Lam3, S Vinod4,5, W Xuan5,6, R Yeghiaian-Alvandi2, E Hau2.   

Abstract

Treatment-related toxicity is an important component in non-small cell lung cancer (NSCLC) management decision-making. Our aim was to evaluate and compare the toxicity rates of curative and palliative radiotherapy with and without chemotherapy. This meta-analysis provides better quantitative estimates of the toxicities compared to individual trials. A systematic review of randomised trials with > 50 unresectable NSCLC patients, treated with curative or palliative conventional radiotherapy (RT) with or without chemotherapy. Data was extracted for oesophagitis, pneumonitis, cardiac events, pulmonary fibrosis, myelopathy and neutropenia by any grade, grade ≥ 3 and treatment-related deaths. Mantel-Haenszel fixed-effect method was used to obtain pooled risk ratio. Forty-nine trials with 8609 evaluable patients were included. There was significantly less grade ≥ 3 acute oesophagitis (6.4 vs 22.2%, p < 0.0001) and any grade oesophagitis (70.4 vs 79.0%, p = 0.04) for sequential CRT compared to concurrent CRT, with no difference in pneumonitis (grade ≥ 3 or any grade), neutropenia (grade ≥ 3), cardiac events (grade ≥ 3) or treatment-related deaths. Although the rate of toxicity increased with intensification of treatment with RT, the only significant difference between treatment regimens was the rate of oesophagitis between the use of concurrent and sequential CRT. This can aid clinicians in radiotherapy decision making for NSCLC.

Entities:  

Mesh:

Year:  2021        PMID: 33723301      PMCID: PMC7971013          DOI: 10.1038/s41598-021-85131-7

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.996


  80 in total

1.  Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 Study.

Authors:  Pierre Fournel; Gilles Robinet; Pascal Thomas; Pierre-Jean Souquet; Hervé Léna; Alain Vergnenégre; Jean-Yves Delhoume; Jacques Le Treut; Jules-Antoine Silvani; Eric Dansin; Marie-Cécile Bozonnat; Jean-Pierre Daurés; Françoise Mornex; Maurice Pérol
Journal:  J Clin Oncol       Date:  2005-08-08       Impact factor: 44.544

2.  Radiotherapy or chemotherapy followed by radiotherapy with or without amifostine in locally advanced lung cancer.

Authors:  Dosia Antonadou
Journal:  Semin Radiat Oncol       Date:  2002-01       Impact factor: 5.934

3.  Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial.

Authors:  M Guberina; W Eberhardt; M Stuschke; T Gauler; F Heinzelmann; D Cheufou; M Kimmich; G Friedel; H Schmidberger; K Darwiche; V Jendrossek; M Schuler; G Stamatis; C Pöttgen
Journal:  Ann Oncol       Date:  2017-05-01       Impact factor: 32.976

4.  Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non-Small-Cell Lung Cancer.

Authors:  Robert T Dess; Yilun Sun; Martha M Matuszak; Grace Sun; Payal D Soni; Latifa Bazzi; Venkatesh L Murthy; Jason W D Hearn; Feng-Ming Kong; Gregory P Kalemkerian; James A Hayman; Randall K Ten Haken; Theodore S Lawrence; Matthew J Schipper; Shruti Jolly
Journal:  J Clin Oncol       Date:  2017-03-16       Impact factor: 44.544

Review 5.  Adverse event reporting in cancer clinical trial publications.

Authors:  Shanthi Sivendran; Asma Latif; Russell B McBride; Kristian D Stensland; Juan Wisnivesky; Lindsay Haines; William K Oh; Matthew D Galsky
Journal:  J Clin Oncol       Date:  2013-12-09       Impact factor: 44.544

6.  Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.

Authors:  Karen Kelly; Kari Chansky; Laurie E Gaspar; Kathy S Albain; James Jett; Yee C Ung; Derick H M Lau; John J Crowley; David R Gandara
Journal:  J Clin Oncol       Date:  2008-03-31       Impact factor: 44.544

7.  Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2017-09-08       Impact factor: 91.245

8.  PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Suresh Senan; Anthony Brade; Lu-Hua Wang; Johan Vansteenkiste; Shaker Dakhil; Bonne Biesma; Maite Martinez Aguillo; Joachim Aerts; Ramaswamy Govindan; Belén Rubio-Viqueira; Conrad Lewanski; David Gandara; Hak Choy; Tony Mok; Anwar Hossain; Neill Iscoe; Joseph Treat; Andrew Koustenis; Bélen San Antonio; Nadia Chouaki; Everett Vokes
Journal:  J Clin Oncol       Date:  2016-01-25       Impact factor: 44.544

9.  Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007.

Authors:  Sarah Walters; Camille Maringe; Michel P Coleman; Michael D Peake; John Butler; Nicholas Young; Stefan Bergström; Louise Hanna; Erik Jakobsen; Karl Kölbeck; Stein Sundstrøm; Gerda Engholm; Anna Gavin; Marianne L Gjerstorff; Juanita Hatcher; Tom Børge Johannesen; Karen M Linklater; Colleen E McGahan; John Steward; Elizabeth Tracey; Donna Turner; Michael A Richards; Bernard Rachet
Journal:  Thorax       Date:  2013-02-11       Impact factor: 9.139

10.  A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L.

Authors:  Tomonari Sasaki; Takashi Seto; Takeharu Yamanaka; Naonobu Kunitake; Junichi Shimizu; Takeshi Kodaira; Makoto Nishio; Takuyo Kozuka; Toshiaki Takahashi; Hideyuki Harada; Naruo Yoshimura; Shinichi Tsutsumi; Hiromoto Kitajima; Masaaki Kataoka; Yukito Ichinose; Kazuhiko Nakagawa; Yasumasa Nishimura; Nobuyuki Yamamoto; Yoichi Nakanishi
Journal:  Br J Cancer       Date:  2018-09-12       Impact factor: 7.640

View more
  1 in total

1.  Relationship between Treatment Plan Dosimetry, Toxicity, and Survival following Intensity-Modulated Radiotherapy, with or without Chemotherapy, for Stage III Inoperable Non-Small Cell Lung Cancer.

Authors:  Isabel F Remmerts de Vries; Merle I Ronden; Idris Bahce; Femke O B Spoelstra; Patricia F De Haan; Cornelis J A Haasbeek; Birgit I Lissenberg-Witte; Ben J Slotman; Max Dahele; Wilko F A R Verbakel
Journal:  Cancers (Basel)       Date:  2021-11-25       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.